ABL001 (Asciminib) is a potent, allosteric BCR-ABL1 kinase inhibitor. It affects the BCR-ABL signaling pathway by binding to the Abl kinase domain, effectively inhibiting the proliferation of chronic myeloid leukemia cells and overcoming TKI resistance.
ABL001 (Asciminib) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for ABL001 (Asciminib) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.
Jump to
- ABL001 (Asciminib) Mechanism of Action: BCR-ABL1 Inhibition in Myeloid Cells Research
- ABL001 (Asciminib) Clinical Trials
- ABL001 (Asciminib): Selectivity & Specificity
- ABL001 (Asciminib) Working Concentration | Cell Culture | Treatment
- ABL001 (Asciminib) Solubility in DMSO
- ABL001 (Asciminib) Stock Solution
- ABL001 (Asciminib) Storage
- ABL001 (Asciminib) Stability
- ABL001 (Asciminib) Combination Database
- ABL001 (Asciminib) Molecular Weight
- ABL001 (Asciminib) SMILES
- ABL001 (Asciminib) CAS Number
- ABL001 (Asciminib) Chemical Structure (2D and 3D)
- ABL001 (Asciminib) Sigma (BL3H160C4B14)? Try a better option.
- ABL001 (Asciminib) APExBIO (BA8800)? Try a better option.
- ABL001 (Asciminib) MedChemExpress (HY-104010)? Try a better option.
- ABL001 (Asciminib) Cayman (26126)? Try a better option.
- ABL001 (Asciminib) SDS｜MSDS